ClinicalTrials.gg
CompletedNCT06481293Updated Sep 25, 2025

Tackling Dry Socket Via Laser Therapy in Smokers

An interventional study of Diode laser therapy and Alveogyl dressing in Alveolar Osteitis, sponsored by Badr University. Completed at 1 site in Egypt. Open to participants aged 25 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Badr University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2023, registered Jun 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
25 Years to 40 Years
Sex
All
01

Study summary

This study examines the efficiency of diode laser therapy to manage dry sockets after tooth extraction.

Read the detailed description

The study compares the efficiency of diode laser therapy and using only alveogyl to accelerate the healing of dry sockets after tooth extraction in smokers. Smoker patients with dry sockets were enrolled randomly into two different groups. Group 1 received dual wavelength laser diode therapy, three times per week. While group 2 received only a topical application of alveogl. The treatment lasted for two consecutive weeks. The treatment efficiency was evaluated by measuring the volume of the socket using the syringe method. The pain level was measured by the visual analog scale.

02

Conditions studied

  • Alveolar Osteitis

Browse trials for

Keywords

  • Diode laser
  • Dry socket
03

In context

Dry Socket

46 studies on the registry are indexed under Dry Socket; 10 are open to participants now.

This study's enrollment of 50 is below the median of 60 across 41 interventional studies indexed under Dry Socket.

Browse Dry Socket studies →

Lead sponsor

Badr University is the lead sponsor of 64 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Smokers patient

Exclusion criteria

Exclusion Criteria:

  • Females on .
  • Diabetic patients
  • virus patients
  • Patients on
  • Patients with renal diseases
  • Anemic patients
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Group 1

    Group 1 received diode laser therapy

    Device: Diode laser therapy

  • Experimental
    group 2

    Group 2 received topical application of aveogl dressing

    Combination Product: Alveogyl dressing

Interventions

  • DeviceDiode laser therapy

    Dual wavelength laser diode therapy device

  • Combination productAlveogyl dressing

    Alveogyl is a haemostatic-analgesic alveolar dressing

06

What researchers measure

Primary outcomes

  1. Socket volume

    measured through the volumetric measurement method using a syringe filled with saline

    Time frame: 2 weeks

Secondary outcomes

  1. Pain level

    measured by the visual analogue scale(VAS). It include score from 0 to 10 in which 10 indicates the worst pain level and 0 indicates no pain

    Time frame: 2 weeks

07

Study locations

1 site
  • Badr University in Cairo
    Cairo, 11837, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06481293
Lead sponsor
Badr University
Responsible party
Reham Alaa (lecturer of physical therapy, Badr University) — Principal investigator
First posted
Jul 1, 2024
Start date
Oct 30, 2023
Primary completion
Sep 20, 2024
Completion
Sep 20, 2025
Last update
Sep 25, 2025

Study contacts

reham Elkalla, lecturer
principal investigator · Badr University in Cairo

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion